Trial Profile
A Randomized, Subject and Investigator Blinded, Placebo Controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs LYS-006 (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 21 Mar 2022 Status changed from active, no longer recruiting to completed.
- 18 Mar 2022 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 04 Mar 2022 Planned End Date changed from 14 Mar 2022 to 9 Mar 2022.